Table 1.
Baseline Demographic, Anthropometric and Clinical Characteristics of the LIVES Trial Participants (N= 1205)
| Characteristics | Number (%) of total sample enrolled |
|---|---|
| Demographics | |
| Age (years) [mean (SD)] | 59.57 (9.7) |
| Race / ethnicity | |
| White | 1018 (89.0) |
| Black | 57 (5.0) |
| American Indian/ Alaskan Native / Native Hawaiian | 14 (1.2) |
| Asian | 27 (2.4) |
| Other/ More than 1 race selected | 28 (2.5) |
| Ethnicity | |
| Non-Hispanic | 1077 (94.5) |
| Hispanic | 63 (5.5) |
| Education | |
| Less than college | 185 (16.2) |
| Some college | 324 (28.3) |
| College graduate | 636 (55.6) |
| Marital Status | |
| Married | 807 (7.4) |
| Separated | 174 (15.2) |
| Widowed | 73 (6.4) |
| Never married | 92 (8.0) |
| Clinical | |
| Body Mass Index | |
| Normal (≤24.9 kg/m2) | 437 (36.4) |
| Overweight (25.0–29.9 kg/m2) | 401 (33.4) |
| Obese (≥30.0 kg/m2) | 363 (30.2) |
| Waist Circumference | |
| <88 cm | 483 (40.3) |
| ≥88 cm | 715 (59.7) |
| Stage of disease | |
| II | 188 (15.6) |
| III | 836 (69.4) |
| IV | 181 (15.0) |
| Disease Site | |
| Ovary | 894 (74.9) |
| Fallopian Tube | 118 (3.9) |
| Peritoneum | 111 (9.3) |
| Pathology | |
| Serous Adenocarcinoma | 991 (82.2) |
| Endometrioid Adenocarcinoma | 64 (5.3) |
| Clear Cell Carcinoma | 56 (4.7) |
| Adenocarcinoma, unspecified | 43 (3.6) |
| Mixed Epithelial Carcinoma | 30 (2.5) |
| Other | 21 (1.7) |
| Histology | |
| Well differentiated | 54 (4.8) |
| Moderately differentiated | 62 (6.0) |
| Poorly differentiated | 918 (88.8) |
| Consolidation therapy (% ) | 272 (22.6) |
| Hormone therapy (%) | 336 (29.6) |
| Family history of cancer (%) | 776 (67.8) |
| BRCA mutation carrier (%) | 125 (10.9) |
| Medical History | |
| Number live births [mean (SD)] | 2.00 (1.4) |
| Infertility | 74 (6.5) |
| Diabetes | 80 (7.0) |
| Hypertension | 395 (34.5) |
| Hyperthyroidism | 65 (5.8) |
| Hypothyroidism | 213 (18.8) |
| Hyperlipidemia | 407 (35.6) |
| Myocardial infarction or stroke | 29 (2.5) |
| Osteoporosis | 129 (11.3) |
| Medication use | |
| Oral contraceptives | 731 (63.8) |
| Hormone therapy | 336 (29.6) |
| Aspirin | 319 (27.9) |
| Bisphosphonate | 102 (8.9) |
| Tamoxifen | 27 (2.4) |
Missing data <10%